TYK2 gene – Talk Bio

Zenas BioPharma Inks $2 Billion+ Licensing Deal With InnoCare for Autoimmune Drug Candidates

1 week ago talkbio0Tagged Autoimmune Diseases, BTK inhibitor, Clinical Trials, Inhibitor, InnoCare, Interleukin-17, Multiple Sclerosis, orelabrtuinib, Pharma, TYK2 gene, Zenas BioPharma

Zenas BioPharma; InnoCare Pharma; autoimmune diseases; multiple sclerosis; BTK inhibitor; orelabrtuinib; licensing deal; clinical trials; IL-17 inhibitor; TYK2 inhibitor

Next-Generation Psoriasis Drugs Aim to Reshape Treatment Landscape

4 weeks ago talkbio0Tagged Approved, Clinical Trials, icotrokinra, inhibitors, interleukin-23, next-generation biologics, oral peptides, Piclidenoson, TYK2 gene, United States Food and Drug Administration, Vunakizumab

psoriasis; next-generation biologics; icotrokinra; IL-23 inhibitors; oral peptides; TYK2 inhibitors; vunakizumab; piclidenoson; clinical trials; FDA approval

Kaken Secures Japanese Rights for Alumis’ Novel TYK2 Inhibitor ESK-001

7 months ago talkbio0Tagged Alumis, Dermatology field, Dosage Forms, ESK-001, Inhibitor, Japan, Kaken, licensing agreement, TYK2 gene

Alumis, Kaken Pharmaceutical, ESK-001, TYK2 inhibitor, dermatology, licensing agreement, Japan

Sotyktu Shows Promise in Phase 3 Psoriatic Arthritis Trial

7 months ago talkbio0Tagged Arthritis, Psoriatic, deucravacitinib, Inhibitor, Myers, POETYK, PsA-2 trial, Sotyktu, squibb, TYK2 gene

Sotyktu, deucravacitinib, psoriatic arthritis, Bristol Myers Squibb, POETYK PsA-2 trial, TYK2 inhibitor

Sotyktu Expands Potential with Successful Phase III Trials in Psoriatic Arthritis

10 months ago talkbio0Tagged Arthritis, Psoriatic, deucravacitinib, Inhibitor, Myers, Phase 3 Clinical Trials, Sotyktu, squibb, TYK2 gene

Sotyktu, deucravacitinib, psoriatic arthritis, Phase III trials, Bristol Myers Squibb, TYK2 inhibitor

Kymera Therapeutics Shifts Focus to Immunology, Scaling Back Oncology Efforts

12 months ago talkbio0Tagged Immunology, IRAK4 gene, Kymera, Neoplasms, Protein Degradation, Metabolic, STAT6, TYK2 gene

Kymera Therapeutics, Immunology, Oncology, Targeted Protein Degradation, IRAK4, STAT6, TYK2

Ventyx Abandons TYK2 Inhibitor Development Following Phase II Failure in Crohn’s Disease

1 year ago talkbio0Tagged Biosciences, Crohn 's disease, Drug Development, Failure (biologic function), Inhibitor, Phase 2 Clinical Trials, TYK2 gene, Ventyx, VTX958

Ventyx Biosciences, TYK2 inhibitor, VTX958, Crohn’s disease, Phase II trial, drug development failure

Ventyx Discontinues TYK2 Inhibitor Programme Following Second Mid-Stage Setback

1 year ago talkbio0Tagged Arthritis, Psoriatic, Biosciences, Crohn 's disease, Drug Development, Inflammatory disorder, Inhibitor, Phase 2 Failure, Psoriasis, TYK2 gene, Ventyx, VTX958

Ventyx Biosciences, TYK2 inhibitor, VTX958, Phase 2 failure, psoriasis, psoriatic arthritis, Crohn’s disease, inflammatory diseases, drug development.